Myeloid Malignancies clinical trials at University of California Health
2 in progress, 1 open to eligible people
Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
open to eligible people ages 18 years and up
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and clinical activity of KT-253 in adult patients with relapsed or refractory (R/R) high grade myeloid malignancies, acute lymphocytic leukemia (ALL), R/R lymphoma, and R/R solid tumors. The study will identify the pharmacologically optimal dose(s) of KT-253 as the recommended Phase 2 dose (RP2D), based on all safety, PK, PD, and efficacy data.
at UC Davis
Magrolimab Combinations in Participants With Myeloid Malignancies
Sorry, in progress, not accepting new patients
The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab (Mag), in combination with anti-leukemia therapies in participants with acute myeloid leukemia (AML).
at UCLA
Our lead scientists for Myeloid Malignancies research studies include Wanxing Chai-ho.
Last updated: